Filing Flows › Zoetis (ZTS) › Pain and sedation revenue
Zoetis (ZTS) Pain and sedation revenue by quarter
Zoetis' Pain and sedation revenue was $200M in Q3 2026 (third quarter 2026), -8% from Q2 2026. Over the last 5 quarters it ranged from $200M (Q3 2026) to $217M (Q2 2026).
| Quarter | Pain and sedation revenue | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $200M | -8% | — |
| Q2 2026 | $217M | +7% | 0% |
| Q1 2026 | $203M | -6% | -3% |
| Q2 2025 | $217M | +3% | — |
| Q1 2025 | $210M | — | — |
Q3 2026 at a glance
Zoetis, Q3 2026: revenue $2.4B (-1% year over year), operating margin 30.5%, net earnings $591M, operating cash flow $824M. The chart follows the revenue to costs, profit and cash.
Questions
What is Zoetis' Pain and sedation revenue?
Zoetis' Pain and sedation revenue was $200M in Q3 2026 (third quarter 2026), -8% from Q2 2026.
How has Zoetis' Pain and sedation revenue changed?
Over the last 5 quarters it ranged from $200M (Q3 2026) to $217M (Q2 2026).